Circulating Thrombospondin-2 Reflects Disease Severity and Predicts Outcome of Heart Failure With Reduced Ejection Fraction

• Hanatani Shinsuke

  Department of Cardiovascular Medicine, Graduate School of Medical Sciences

• Izumiya Yasuhiro

  Department of Cardiovascular Medicine, Graduate School of Medical Sciences

• Takashio Seiji

  Department of Cardiovascular Medicine, Graduate School of Medical Sciences

• Kimura Yuichi

  Department of Cardiovascular Medicine, Graduate School of Medical Sciences

• Araki Satoshi

  Department of Cardiovascular Medicine, Graduate School of Medical Sciences

• Rokutanda Taku

  Department of Cardiovascular Medicine, Graduate School of Medical Sciences

• Tsujita Kenichi

  Department of Cardiovascular Medicine, Graduate School of Medical Sciences

• Yamamoto Eiichiro

  Department of Cardiovascular Medicine, Graduate School of Medical Sciences

• Tanaka Tomoko

  Department of Cardiovascular Medicine, Graduate School of Medical Sciences

• Yamamuro Megumi

  Department of Cardiovascular Medicine, Graduate School of Medical Sciences

• Kojima Sunao

  Department of Cardiovascular Medicine, Graduate School of Medical Sciences

• Tayama Shinji

  Department of Cardiovascular Medicine, Graduate School of Medical Sciences

• Kaikita Koichi

  Department of Cardiovascular Medicine, Graduate School of Medical Sciences

• Hokimoto Seiji

  Department of Cardiovascular Medicine, Graduate School of Medical Sciences

• Ogawa Hisao

  Department of Cardiovascular Medicine, Graduate School of Medical Sciences

Abstract

Background: Thrombospondin-2 (TSP-2) is a matricellular protein found in human serum. Deletion of TSP-2 causes age-dependent dilated cardiomyopathy. We hypothesized that TSP-2 is a useful biomarker in patients with heart failure with reduced ejection fraction (HFrEF). Methods and Results: Serum TSP-2 was measured in 101 patients with HFrEF, and mortality and cardiovascular events were followed. Serum TSP-2 in the HFrEF group was significantly higher than in the non-HF group (n=17). Mean NYHA functional class was significantly higher in the high TSP-2 group (>median) than the low TSP-2 group (2.26 vs. 1.76, P=0.004). Circulating TSP-2 level was significantly associated with that of B-type natriuretic peptide (BNP; r=0.40, P<0.0001) on multivariate linear regression analysis. On Kaplan-Meier curve analysis the high TSP-2 group had a lower event-free rate than the low TSP-2 group (log-rank test, P=0.03). Multivariate Cox hazard analysis identified hemoglobin (hazard ratio [HR], 0.66; 95% confidence interval [CI]: 0.53–0.82, P<0.0001), and TSP-2 (ln[TSP-2]; HR, 3.34; 95% CI: 1.03–10.85, P=0.045) as independent predictors of adverse outcome. The area under the curve for 1-year events increased when TSP-2 was added to Framingham risk score (FRS; alone, 0.60) or BNP (alone, 0.69; FRS+TSP-2, 0.75; BNP+TSP-2, 0.76). Conclusions: TSP-2 is a potentially useful biomarker for assessment of disease severity and prognosis in HFrEF.  (Circ J 2014; 78: 903–910)<br>

Journal

• Circulation Journal

  Circulation Journal 78 (4), 903-910, 2014

  The Japanese Circulation Society

Keywords

• Biomarker
• Heart failure
• Matricellular protein
• Prognosis

Details

• CRID: 1390282680085714816
• NII Article ID: 130003391038
• NII Book ID: AA11591968
• DOI: 10.1253/circj.cj-13-1221
• COI: 1:STN:280:DC%2BC2cvisVertQ%3D%3D
• ISSN: 13474820
• ISSN: 13469843
• NDL BIB ID: 025356135
• PubMed: 24500070
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I025356135
• Web Site: https://www.jstage.jst.go.jp/article/circj/78/4/78_CJ-13-1221/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2014270582
• Text Lang: en
• Data Source:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed